Trial watch: Antisense agent reduces LDL-cholesterol levels in high-risk patients.
D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects*; D017326:Clinical Trials, Phase III as Topic; D016503:Drug Delivery Systems; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D009841:Oligonucleotides / Q000494:pharmacology / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D009841:Oligonucleotides; C524142:mipomersen